Research into shortness of breath: EU funds the development of immune cell therapy for pulmonary fibrosis

Hinweis zur Verwendung von Bildmaterial: Die Verwendung des Bildmaterials zur Pressemitteilung ist bei Nennung der Quelle vergütungsfrei gestattet. Das Bildmaterial darf nur in Zusammenhang mit dem Inhalt dieser Pressemitteilung verwendet werden. Falls Sie das Bild in höherer Auflösung benötigen oder Rückfragen zur Weiterverwendung haben, wenden Sie sich bitte direkt an die Pressestelle, die es veröffentlicht hat.

Prof. Dr. Nico Lachmann examines macrophages under a microscope. The photograph shows the flags of the countries taking part in the project. | Copyright: Karin Kaiser/MHH | Download

In pulmonary fibrosis, the tissue between the small air sacs in the lungs becomes scarred; as the disease progresses, this leads to increasing shortness of breath due to stiffening of the lungs, and a lung transplant may even become necessary. There is currently no cure for pulmonary fibrosis. The causes are often unknown, and the clinical presentations vary greatly. To date, treatments have been limited to slowing the progression of the disease. Ideally, the scarring and stiffening can be halted. However, it is usually not possible to reverse the tissue damage that has already occurred.

A team of researchers at Hannover Medical School (MHH) is now working intensively on new, effective treatment options as part of the new BREATH-EC project – in collaboration with other university hospitals and companies from Germany, Sweden, England, South Korea, Portugal, Ireland, Italy and Belgium. From Germany, the Helmholtz Centre for Infection Research (HZI), the Fraunhofer Institute for Toxicology and Experimental Medicine and the University Medical Centre Freiburg are involved. The European Union (EU) is funding this project with around ten million euros. Of this, the MHH will receive 2.73 million euros. The project is scheduled to run for four years.

“Our aim is to use certain immune cells to halt the progression of pulmonary fibrosis and possibly even reverse it. To do this, we are using genetically modified macrophages,” says Prof. Dr. Nico Lachmann from the Department of Paediatric Pneumology, Allergology and Neonatology at the MHH. He is coordinating a four-year EU collaborative project.

Immune cells recognise and inhibit fibrosis

Macrophages – also known as ‘scavenger cells’ – play a central role in the human immune system. They are essential for defending against pathogens and for repairing damaged tissue. The research team generates these macrophages from so-called induced pluripotent stem cells (iPS cells) or isolates them from donor blood. “We then genetically modify the macrophages. This enables them both to recognise early signs of fibrosis in the lungs and to act directly against it,” explains Professor Lachmann. “The macrophages intercept signalling molecules that promote fibrosis and produce antibodies locally that inhibit fibrosis.”

The long-term aim of the project is to administer the genetically modified macrophages to patients via bronchoscopy. The aim is to halt – and possibly even reverse – fibrosis in the lungs, at least in the early stages of the disease. Furthermore, the research findings are expected to benefit the development of further innovative treatments for fibrotic diseases, including those affecting the liver and the heart.

Cell and gene therapies for lung diseases

Macrophages are versatile immune cells which, in the lungs, are found – amongst other forms – as alveolar macrophages in the alveoli. There, they orchestrate inflammatory processes and regulate various cell types. The research team is utilising the unique function of macrophages and aims to use these optimised cells to restore balance to the dysregulated inflammation. This type of cell therapy holds promise for a range of lung diseases. This is because the potential to equip immune cells with novel, therapeutically relevant genes – and thereby enhance their function – offers a wide range of applications. The BREATH-EC project thus fulfils a key objective of the German government’s High-Tech Agenda in the field of cell and gene therapies, as well as that of the Centre for Gene and Cell Therapy at the MHH.

The Lower Saxony Ministry of Science and Culture provided financial support for the application. Professor Lachmann is a researcher at the RESIST Cluster of Excellence and at the German Centre for Lung Research (DZL) in Hanover, which is based at the MHH. At the DZL, he is investigating the role of macrophages in various lung diseases with a view to developing new cell and gene therapy approaches specifically targeting these phagocytes.

In addition to Professor Lachmann, the BREATH-EC project at the MHH also involves PD Dr. Ruth Olmer, Prof. Dr. Ulrich Martin, Prof. Dr. Ulrich Maus and Prof. Dr. Jonas Schupp. Together with the other partners in the international consortium, they are driving forward this novel therapeutic approach.

SERVICE

For further information, please contact Prof. Dr. Nico Lachmann, Lachmann.Nico@mh-hannover.de.